at Zacks.com (Thu, 9:32AM)
Abbott Labs (ABT +0.5%) launches its XIENCE Xpedition drug-eluting coronary stent, which slowly releases a medicine to block cell proliferation, after receiving FDA approval for the device. "XIENCE Xpedition represents a powerful combination of deliverability, strong clinical data and broad availability of meaningful sizes," says Dr Samin Sharma of Mount Sinai Medical Center in New York. (PR)
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Nasdaq.com (Jan 20, 2015)
at Zacks.com (Jan 14, 2015)
Abbott Laboratories (ABT): New Analyst Report from Zacks Equity Research - Zacks Equity Research Reportat Zacks.com (Jan 14, 2015)
at CNBC.com (Jan 13, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs